60 Degrees Pharmaceuticals, Inc.
NCM: SXTPLive Quote
📈 ZcoreAI Score
Our AI model analyzes 60 Degrees Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SXTP Z-Score →About 60 Degrees Pharmaceuticals, Inc.
Healthcare
Biotechnology
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
📊 Fundamental Analysis
60 Degrees Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 16.2% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -200.9%, which indicates that capital utilization is currently under pressure.
At a current price of $1.76, SXTP currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $1.29 - $17.68).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$4.64M
Trailing P/E
--
Forward P/E
-0.22
Beta (5Y)
3.28
52W High
$17.68
52W Low
$1.29
Avg Volume
4.65M
Day High
Day Low